62
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Clofarabine: a size that fits all, may not fit all

, MD
Pages 309-310 | Published online: 01 Jul 2009

References

  • Kantarjian H M, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21: 1167–1173
  • Jeha S, Gandhi V, Chan K W, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103: 784–789
  • Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine inpatients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379–2386
  • Erba H P, Kantarjian H, Claxton D F, et al. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. Blood 2008; 112: 558, (abstract)
  • Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105: 940–947
  • Nabhan C, Fried W, Galvez A, et al. Phase I/II trial of clofarabine in refractory and/or relapsed non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 2008; 26: 8564, (abstract)
  • Uy G L, Tomasson M H, Ruddell A, et al. The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma. Haematologica 2006; 91: 1581–1582
  • Cunningham C C, Nemunaitis J, Senzer N, et al. Clofarabine administration weekly to adult patients with advanced solid tumors in a phase I dosefinding study. Proc Am Soc Clin Oncol 2005; 23: 7109, (abstract)
  • Faderl S, Garcia-Manero G, Ravandi F, et al. Oral (po) and intravenous (iv) clofarabine for patients (pts) with myelodysplastic syndrome (MDS). Blood 2008; 112: 222, (abstract)
  • Martin M G, Uy G, Procknow E, et al. Allogeneic stem cell transplantation conditioning for myelodysplatic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplant Accepted
  • Klyuchnikov E, Kröger N. Sensitising leukemic cells by targeting microenvironment. Leuk Lymphoma 2009; 50: 319–320

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.